Skip to main content

Table 1 Percentage of CD14+CD16+ cells in total PBMC and CD16int cells in Ps, PsA, RA and HC populations

From: CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis

(a)

(b)

(c)

 

Number of subjectsb

% of subjectc

% of CD14+CD16+ in total PBMCa

with CD16int

without CD16int

with CD16int

Ps (n = 29) 0.82 ± 0.60

25

4

86

PsA (n = 29) 0.91 ± 0.62

19

9

67

RA (n = 8) 0.57 ± 0.21

5

3

61

HC (n = 16) 0.46 ± 0.30

8

11

42

  1. a Total PBMC were purified by Ficoll gradient, stained with PE-CD16, allophycocyanin (APC)-CD14 antibodies and analyzed by flow cytometry. Dead cells were excluded by 7-amino-actinomycin D (AAD).
  2. b Number of subjects with or without CD16int. CD16int cells.c Percentage of subjects with CD16int.
  3. HC = healthy control; PBMC = peripheral blood mononuclear cells; Ps = psoriasis; PsA = psoriatic arthritis; RA = rheumatoid arthritis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us